you are here: Home News Biosimilar

Biosimilar

Lupin launches Glucagon injection, targets $122 million annual market in US for low blood sugar
Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant
Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan
Biocon Biologics receives European Commission approval for ophthalmology biosimilar Yesafili
Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe
Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug
Lupin: Pricing erosion intensifies in US
Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward
Cadila: All in for COVID while keeping a tab on complex pharma
Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy
Plan to enter EU market with Insulin Glargine in second half of the year: Biocon
Glenmark gets USFDA nod to test anti-asthma biosimilar omalizumab on humans
Aurobindo sees R&D costs to double as it gets into biosimilars
Aurobindo forays into biosimilars with Swiss acquisition
I don't see Trump's views affecting Indian drug cos: Biocon CMD
USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Fosun Pharma best fit due to global presence, size: Gland Pharma
Regulatory issues discussed in Feb meet with US, Europe: DRL
HC allows Biocon, Mylan to continue manufacturing cancer drugs
We try to launch products at one-fifth global price: Cadila
Biocon-Mylan start phase-3 global trials for drug Glargine
Cipla launches biosimilar for rheumatic disorders in India
Mylan-Biocon partnership gives access to key markets: Shaw

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Biosimilar

Lupin launches Glucagon injection, targets $122 million annual market in US for low blood sugar

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan

Biocon Biologics receives European Commission approval for ophthalmology biosimilar Yesafili

Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe

Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug

Lupin: Pricing erosion intensifies in US

Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Cadila: All in for COVID while keeping a tab on complex pharma

Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy

Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

Glenmark gets USFDA nod to test anti-asthma biosimilar omalizumab on humans

Aurobindo sees R&D costs to double as it gets into biosimilars

Aurobindo forays into biosimilars with Swiss acquisition

I don't see Trump's views affecting Indian drug cos: Biocon CMD

USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

Fosun Pharma best fit due to global presence, size: Gland Pharma

Regulatory issues discussed in Feb meet with US, Europe: DRL

HC allows Biocon, Mylan to continue manufacturing cancer drugs

We try to launch products at one-fifth global price: Cadila

Biocon-Mylan start phase-3 global trials for drug Glargine

Cipla launches biosimilar for rheumatic disorders in India

Mylan-Biocon partnership gives access to key markets: Shaw